Adipose-Resident Immune Cells in Obesity: Mechanisms, Clinical Implications, and Therapeutic Perspectives

Abstract

Obesity is now recognized as a chronic, relapsing metabolic disease with significant global health implications. Central to the pathogenesis of obesity-associated complications is the chronic, low-grade inflammation within adipose tissue, primarily orchestrated by adipose-resident immune cells. This review synthesizes recent advances in our understanding of immune cell dynamics within adipose tissue, elucidates their mechanistic roles in obesity, and explores the clinical relevance, diagnostic considerations, and emerging therapeutic strategies. Special emphasis is placed on evidence-based insights into the interplay between the immune and metabolic systems, highlighting potential avenues for targeted interventions in obesity and its related complications.

Introduction

Obesity remains a pervasive health challenge, affecting over 650 million adults worldwide. Beyond its association with metabolic syndrome, type 2 diabetes, and cardiovascular disease, obesity precipitates a state of chronic inflammation, primarily localized to adipose tissue. In recent years, research has shifted focus to the immune landscape of adipose tissue, recognizing it as a dynamic immunological organ. Adipose-resident immune cells, including macrophages, T cells, B cells, and innate lymphoid cells, play critical roles in maintaining tissue homeostasis and mediating metabolic dysfunction in obesity. Understanding the nuanced crosstalk between these cells and adipocytes is vital for clinicians and researchers seeking innovative approaches to obesity management.

Epidemiology / Disease Burden

Obesity prevalence has reached epidemic proportions globally, with the World Health Organization estimating that 13% of the world’s adult population is classified as obese. The burden extends across diverse populations, with disparities influenced by socioeconomic status, ethnicity, and access to healthcare. Obesity-related conditions account for significant morbidity and healthcare costs, particularly through their contribution to cardiovascular disease, diabetes, and non-alcoholic fatty liver disease. The inflammatory milieu within adipose tissue, largely governed by resident immune cells, is now recognized as a fundamental driver of these complications, underscoring the need for a deeper understanding of adipose immunobiology.

Pathophysiology

The pathophysiological link between obesity and systemic metabolic dysfunction is rooted in adipose tissue inflammation. In lean states, adipose tissue harbors a regulatory immune environment dominated by anti-inflammatory M2 macrophages, regulatory T cells (Tregs), and group 2 innate lymphoid cells (ILC2s). With the onset of obesity, there is a phenotypic shift towards pro-inflammatory M1 macrophages, effector T cells (particularly Th1 and CD8+ T cells), and increased infiltration of B cells. These immune cells secrete cytokines such as TNF-α, IL-6, and MCP-1, disrupting adipocyte insulin signaling and promoting insulin resistance. Moreover, adipocyte hypertrophy and hypoxia in expanding adipose tissue exacerbate immune cell recruitment and activation, setting up a self-perpetuating cycle of inflammation and metabolic derangement.

Risk Factors

Key risk factors influencing the composition and activity of adipose-resident immune cells include genetic predisposition, dietary patterns (particularly high-fat, high-sugar diets), sedentary lifestyle, aging, and gut microbiota alterations. Emerging evidence also points to early-life exposures, such as maternal obesity and perinatal nutrition, as modulators of adipose immune programming. These factors not only predispose individuals to obesity but also modulate the inflammatory tone within adipose tissue, thereby impacting disease trajectory and response to interventions.

Clinical Features

Clinically, the impact of adipose-resident immune cells is manifested through the metabolic complications of obesity. These include insulin resistance, glucose intolerance, dyslipidemia, and increased risk of type 2 diabetes and cardiovascular events. While overt clinical signs may be absent in early obesity, laboratory markers such as elevated C-reactive protein, increased pro-inflammatory cytokines, and altered adipokine profiles (e.g., reduced adiponectin, increased leptin) reflect underlying immune activation. Recognition of these features is critical for early identification and risk stratification in clinical practice.

Diagnosis

Diagnosis of obesity-associated adipose inflammation relies on a combination of clinical, biochemical, and imaging modalities. Body mass index (BMI), waist circumference, and body composition assessments remain standard; however, they do not directly measure inflammation. Biomarkers such as high-sensitivity CRP, IL-6, TNF-α, and adiponectin provide indirect evidence of immune activation. Advanced imaging techniques, including PET/CT and MRI, can assess adipose tissue inflammation non-invasively. Novel approaches, such as single-cell transcriptomics and flow cytometry of adipose biopsies, are emerging in research settings to characterize immune cell populations with high precision.

Treatment & Management

Management of obesity and its inflammatory complications is multifaceted, involving lifestyle modification, pharmacotherapy, and in selected cases, bariatric surgery. Caloric restriction and increased physical activity remain foundational, with robust evidence supporting their anti-inflammatory effects on adipose tissue. Pharmacological agents such as GLP-1 receptor agonists and SGLT2 inhibitors demonstrate metabolic benefits and may also modulate immune cell function. Bariatric surgery leads to rapid and sustained reductions in adipose tissue inflammation, partly through alterations in resident immune cell populations. Adjunctive therapies targeting specific inflammatory pathways (e.g., anti-TNF agents, IL-1 antagonists) are under investigation for metabolic indications.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in our understanding of adipose immunobiology. Single-cell sequencing has revealed unprecedented heterogeneity among adipose-resident immune cells, identifying novel subsets with distinct functional roles. Therapeutic strategies targeting immune cell recruitment (e.g., CCR2 antagonists), polarization (e.g., PPARγ agonists), and signaling pathways (e.g., JAK inhibitors) are in various stages of clinical development. Microbiome-targeted interventions and immunometabolic modulators represent promising frontiers, with early-phase studies demonstrating efficacy in modulating adipose inflammation and metabolic outcomes. The translation of these findings into clinical practice requires further validation in large, well-characterized patient cohorts.

Guideline Recommendations

Current international guidelines, including those from the Endocrine Society and the American Diabetes Association, emphasize comprehensive lifestyle interventions as the cornerstone of obesity management. Pharmacological and surgical therapies are reserved for individuals with moderate-to-severe obesity or those with obesity-related comorbidities unresponsive to lifestyle changes. While routine assessment of adipose tissue inflammation is not yet standard practice, recognition of its role in metabolic disease pathogenesis is increasingly reflected in guideline recommendations, particularly in the context of personalized medicine and risk stratification.

Conclusion

The intricate interplay between adipose-resident immune cells and metabolic homeostasis is at the heart of obesity pathogenesis and its complications. Advances in our mechanistic understanding of these processes offer new opportunities for targeted interventions, with the potential to transform clinical outcomes for patients with obesity. As research continues to unravel the complexities of adipose immunology, translation into evidence-based therapies and guidelines will be paramount in addressing the global obesity epidemic.